CLINICAL TRIALS PROFILE FOR CHLOROTHIAZIDE

All Clinical Trials for chlorothiazide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000484 ↗	Treatment of Hypertension	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1966-04-01	To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
NCT00004360 ↗	Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus	Completed	Northwestern University		1995-09-01	OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 ↗	Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-09-01	OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00281671 ↗	Nesiritide Use Following Cardiac Surgery in Infants	Terminated	Boston Children's Hospital	Phase 1/Phase 2	2006-04-08	The purpose of this study is to determine the effects of nesiritide on urine output and hemodynamics following cardiopulmonary bypass in infants. Safety and pharmacokinetic data will also be obtained.
NCT00281671 ↗	Nesiritide Use Following Cardiac Surgery in Infants	Terminated	Boston Children’s Hospital	Phase 1/Phase 2	2006-04-08	The purpose of this study is to determine the effects of nesiritide on urine output and hemodynamics following cardiopulmonary bypass in infants. Safety and pharmacokinetic data will also be obtained.
NCT01721655 ↗	Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease	Unknown status	West Virginia University Healthcare	Phase 2/Phase 3	2012-10-01	Bronchopulmonary dysplasia (BPD), also known as chronic lung disease (CLD), is a major complication of premature birth and is associated with a significant increased risk of complications including death. Diuretics have been used for decades in babies with BPD and are considered a standard of care. Patients receive electrolyte supplementation to replace the electrolytes removed by the diuretics. Spironolactone is not as good as other diuretics at removing extra fluid, but it is different from chlorothiazide and furosemide because instead of removing potassium, it actually can increase potassium levels in our body. Spironolactone is used with chlorothiazide to try to minimize the potassium lost; therefore, reduce the electrolyte supplementation needed. However, studies have suggested that preterm babies aren´t developed enough to appropriately respond to spironolactone. Also, one study has shown that adding spironolactone to chlorothiazide in patients with BPD has no effect on whether or not patients receive electrolyte supplementation. This study will examine whether there is a difference in the amount of electrolyte supplementation between patients receiving chlorothiazide only or chlorothiazide plus spironolactone. the investigators hypothesize there will be no difference in the amount of electrolyte supplementation between the two groups.
NCT02546583 ↗	Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure	Active, not recruiting	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	2015-08-31	Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited. Further, there are therapeutically distinct groups of diuretic-resistant patients. These are not easily distinguished using currently available methods, leading to trial-and-error based treatment that promotes lengthy hospitalizations. The aims of this study are: 1. To develop inexpensive and efficient tools to predict diuretic response 2. To understand the prevalence of therapeutically targetable mechanisms of diuretic resistance using endogenous lithium clearance 3. To develop methodology to differentiate diuretic resistance mechanisms using common/inexpensive laboratory tests 4. To provide proof of concept that mechanistically tailored diuretic therapy can improve natriuresis

Clinical Trial Conditions for chlorothiazide

Condition Name

Condition Name for chlorothiazide
Intervention	Trials
Heart Failure	3
Cardiovascular Diseases	2
Acute Decompensated Heart Failure	1
Hypertension	1

Condition MeSH

Condition MeSH for chlorothiazide
Intervention	Trials
Heart Failure	4
Cardiovascular Diseases	2
Diabetes Insipidus	1
Vascular Diseases	1

Clinical Trial Locations for chlorothiazide

Trials by Country

Trials by Country for chlorothiazide
Location	Trials
United States	6

Trials by US State

Trials by US State for chlorothiazide
Location	Trials
Louisiana	1
Virginia	1
Tennessee	1
Connecticut	1
West Virginia	1

Clinical Trial Progress for chlorothiazide

Clinical Trial Phase

Clinical Trial Phase for chlorothiazide
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for chlorothiazide
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Active, not recruiting	1

Clinical Trial Sponsors for chlorothiazide

Sponsor Name

Sponsor Name for chlorothiazide
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	2
Boston Children's Hospital	1
Boston Children’s Hospital	1

Sponsor Type

Sponsor Type for chlorothiazide
Sponsor	Trials
Other	8
NIH	3